Renal Cell Carcinoma Protocols

MULTI-001 Nivolumab v14

MULTI-003 Pembrolizumab v14

MULTI-018 Larotrectinib v2

MULTI-019 Entrectinib v2

MULTI-022 Ipilimumab in combination with Nivolumab for RCC and previously treated CRC v6

MULTI-027 Cabozantinib (Cabometyx®) v2

RCC-002 Sunitinib v6

RCC-003 Pazopanib v7

RCC-005 Axitinib v4

RCC-008 Lenvatinib (Kisplyx®) & Everolimus (Afinitor®) v1

RCC-009 Tivozanib v3

RCC-011 Avelumab and axitinib v2

RCC-012 Lenvatinib (Kisplyx®) with pembrolizumab v2

RCC-013 Cabozantinib (Cabometyx®) with nivolumab (SC/IV) v2